Progyny, Inc.

PGNY • Medical - Healthcare Information Services

$25.94

▼ -0.67 (-2.52%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$2.20B

Crecimiento

7.4%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Crecimiento positivo de ingresos · 28.1%Flujo de caja libre positivo · 2.25Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.05Liquidez saludable · 2.73

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 7 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$25.94

Change-2.52%

Shares Out84.76M

Market Cap$2.20B

Enterprise Value$1.98B

52W Range16.10 - 28.75

Beta1.04

P/E32.48

P/S1.70

P/B4.85

P/FCF10.23

EV/Sales1.53

Price$25.94

Change-2.52%

Shares Out84.76M

Market Cap$2.20B

Enterprise Value$1.98B

52W Range16.10 - 28.75

Beta1.04

P/E32.48

P/S1.70

P/B4.85

P/FCF10.23

EV/Sales1.53

EV/EBITDA18.35

EV/FCF9.23

Earnings Yield3.08%

FCF Yield9.77%

Dividend Yield0.00%

Gross Margin23.63%

Oper. Margin6.62%

Profit Margin4.54%

Debt/Eq0.05

Current Ratio2.73

Quick Ratio2.73

Revenue 5Y7.40%

Target$35.13

Target Upside35.43%

Target Median$35.50

Target Range30.00 - 40.00

Volume1.24M

Avg Volume1.51M

EPS Surprise0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

33/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

62/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 28.1%Flujo de caja libre positivo · 2.25Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.05Liquidez saludable · 2.73Múltiplo de ganancias caro · 37.4

Analyst view

Analyst sentiment and price target

PGNY

Analyst sentiment

Based on 20 analyst votes · 2026-09-05

85/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-24

Bajo

$27.00

Promedio

$30.33

Mediana

$30.00

Alto

$35.00

Resumen de la compañía

IPO: 10/25/2019

Industria: Medical - Healthcare Information Services

P/B i: 4.85

Deuda / Patrimonio i: 0.05

Margen operativo: 6.62%

Margen neto: 4.54%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.05

Ratio corriente: 2.73

Ratio rápido: 2.73

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Clapp Geoffrey

Transacción: 06/17/2026

VENTA

Cambio

-819

Precio

$26.60

Presentación

06/23/2026

Tipo

VENTA

Swartz Allison

Transacción: 06/04/2026

VENTA

Cambio

-599

Precio

$25.08

Presentación

06/05/2026

Tipo

VENTA

Livingston Mark S.

Transacción: 06/04/2026

VENTA

Cambio

-599

Precio

$25.50

Presentación

06/05/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Clapp Geoffrey	VENTA	-819	$26.60	06/17/2026	06/23/2026
Swartz Allison	VENTA	-599	$25.08	06/04/2026	06/05/2026
Livingston Mark S.	VENTA	-599	$25.50	06/04/2026	06/05/2026
Anevski Peter	VENTA	-5,361	$25.12	06/03/2026	06/05/2026
Swartz Allison	VENTA	-1,199	$25.02	06/03/2026	06/05/2026
Livingston Mark S.	VENTA	-1,082	$25.12	06/03/2026	06/05/2026
Swartz Allison	VENTA	-2,398	$25.46	05/28/2026	06/01/2026
GORDON KEVIN K	VENTA	-2,526	Not reported	05/27/2026	05/29/2026
MORRIS DEBRA L	COMPRA	+5,660	Not reported	05/21/2026	05/26/2026
MORRIS DEBRA L	COMPRA	+3,203	$24.69	05/21/2026	05/26/2026
Scott Cheryl	COMPRA	+5,660	Not reported	05/21/2026	05/26/2026
Scott Cheryl	COMPRA	+27,119	$24.69	05/21/2026	05/26/2026
Payson Norman	COMPRA	+5,660	Not reported	05/21/2026	05/26/2026
Payson Norman	COMPRA	+3,203	$24.69	05/21/2026	05/26/2026
Park Jeffrey G	COMPRA	+5,205	$24.69	05/21/2026	05/26/2026
Park Jeffrey G	COMPRA	+7,924	Not reported	05/21/2026	05/26/2026
HOLSTEIN ROGER C	COMPRA	+6,792	Not reported	05/21/2026	05/26/2026
HOLSTEIN ROGER C	COMPRA	+4,003	$24.69	05/21/2026	05/26/2026
GORDON KEVIN K	COMPRA	+6,792	Not reported	05/21/2026	05/26/2026
GORDON KEVIN K	COMPRA	+30,373	$24.69	05/21/2026	05/26/2026

Sobre la compañía

Progyny, Inc.

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Fuente - Link

Competidores

ALVO GDRX OMCL OMDA PHR SDGR SEM TDOC TXG UFPT

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Progyny, Inc. to Present at the Wells Fargo Healthcare Conference

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.

GlobeNewsWire

Hsbc Holdings PLC Makes New $760,000 Investment in Progyny, Inc. $PGNY

Hsbc Holdings PLC acquired a new stake in shares of Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 26,394 shares of the company's stock, valued at approximately $760,000. Several other large investors have also

Defense World

23,600 Shares in Progyny, Inc. $PGNY Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board acquired a new stake in Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 23,600 shares of the company's stock, valued at approximately $680,000. A number of other hedge funds and other

Defense World

Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen analysts that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating

Defense World

AWM Investment Company Inc. Purchases Shares of 220,000 Progyny, Inc. $PGNY

AWM Investment Company Inc. bought a new position in shares of Progyny, Inc. (NASDAQ: PGNY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 220,000 shares of the company's stock, valued at approximately $6,343,000. AWM Investment Company Inc. owned about 0.29% of

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	0.256	0.29	0.034
2026-02-26	0.147	0.15	0.003
2025-11-06	0.39	0.45	0.06
2025-08-07	0.44	0.48	0.04
2025-05-08	0.45	0.48	0.03
2025-02-27	0.37	0.42	0.05
2024-11-12	0.37	0.4	0.03
2024-08-06	0.36	0.43	0.07
2024-05-09	0.14	0.39	0.25
2024-02-27	0.11	0.32	0.21
2023-11-07	0.12	0.16	0.04
2023-08-03	0.1	0.15	0.05